Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osimertinib + rifampicin
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations. Rifampicin is a strong CYP3A4 inducer antibiotic used for tuberculosis and other infections. The combination "osimertinib + rifampicin" refers to the co-administration of these two drugs, which results in significant pharmacokinetic interactions—rifampicin markedly reduces osimertinib plasma concentrations by increasing its metabolism via CYP3A4 induction[1][3][6]. This interaction may reduce the efficacy of osimertinib unless dose adjustments are made[1][6].
- Brand names
- Tagrisso (for Osimertinib)no unique brand name for combination
- Other names
- osimertinib and rifampicinosimertinib with rifampicin
02
Targets
EGFR (Epidermal growth factor receptor)CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on osimertinib + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osimertinib + rifampicin.